A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

WHO Grade II Glioma Clinical Trial

Official title:
A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma

Status Active, not recruiting

Clinical Trial Summary

This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04458272
Study type	Interventional
Source	Daiichi Sankyo, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 8, 2020
Completion date	June 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04479696` - Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors	N/A
Recruiting	`NCT03251027` - Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma	N/A
Recruiting	`NCT04623931` - Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas	Phase 2
Recruiting	`NCT04540107` - Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma	Phase 1
Recruiting	`NCT03749187` - BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas	Phase 1